

Title	Trial of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial
Authors	Mone, Fionnuala;Mulcahy, Cecilia;McParland, Peter;Breathnach, Fionnuala M.;Downey, Paul;McCormack, Dorothy;Culliton, Marie;Stanton, Alice;Cody, Fiona;Morrison, John J.;Daly, Sean;Higgins, John R.;Cotter, Amanda;Hunter, Alyson;Tully, Elizabeth C.;Dicker, Patrick;Alfirevic, Zarko;Malone, Fergal D.;McAuliffe, Fionnuala M.
Publication date	2018
Original Citation	Mone, F., Mulcahy, C., McParland, P., Breathnach, F., Downey, P., McCormack, D., Culliton, M., Stanton, A., Cody, F., Morrison, J. J., Daly, S., Higgins, J., Cotter, A., Hunter, A., Tully, E. C., Dicker, P., Alfirevic, Z., Malone, F. D. and McAuliffe, F. M. (2018) 'Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial', BMJ Open, 8(7), e022056 (9pp). doi: 10.1136/bmjopen-2018-022056
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://bmjopen.bmj.com/content/8/7/e022056 - 10.1136/bmjopen-2018-022056
Rights	© 2018, the Author(s) [or their employer(s)]. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . - http://creativecommons.org/licenses/by-nc/4.0/
Download date	2025-09-11 08:38:52

Item downloaded
from

<https://hdl.handle.net/10468/6940>



UCC

University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

Outcome	Low Dose Aspirin (Group 1) N=179	No Aspirin (Group 2) N=183	Screen and Treat (Group 3) N=184
Gestation at delivery (wks)	40.2 (1.4)	39.9 (1.9)	40.2 (1.5)
Birthweight (g)	3529 (469)	3478 (493)	3488 (502)
Birthweight <10 th centile No. (%)	14 (8%)	18(10%)	25 (14%)
Mode of delivery No. (%)			
Spontaneous	85 (47.5)	95 (52.0)	88 (47.8)
Instrumental	56 (31.3)	47 (25.7)	51 (27.7)
Caesarean	38 (21.2)	41 (22.3)	45 (24.5)
Pre-term delivery <34 weeks No. (%)	1 (0.6)	3 (1.6)	2 (1.1)
Spontaneous Labor No. (%)	96 (53.7)	103 (56.3)	101 (54.9)
Preeclampsia No. (%)	8 (4.5)	7 (3.8)	7 (3.8)
Preeclampsia <34-weeks	0 (0)	2 (1.1)	1 (0.5)
Preeclampsia <37-weeks	2 (1.1)	2 (1.1)	2 (1.1)
Abruption No. (%)	1 (0.5)	0 (0)	0 (0)
NICU admission No. (%)	9 (5.0)	7 (3.8)	9 (4.9)
Apgar < 7 No. (%)	5 (2.8)	2 (1.6)	3 (1.6)
Cord pH (arterial)	7.3 (0.1)	7.3 (0.1)	7.3 (0.1)
Outcome No. (%)			
Alive at 6-weeks	177 (98.9)	181 (99.0)	182 (98.9)
Stillbirth	2 (1.1)	1 (0.5)	0 (0)
Neonatal death	0 (0)	1 (0.5)	2 (1.1)

Table S1: Secondary outcome measures

(Expressed as average and standard deviation unless otherwise stated)